About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? - Suppr | 超能文献

About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?

作者信息

Aragon-Ching J B, Dahut W L

出版信息

Ann Oncol. 2010 Jan;21(1):183-4. doi: 10.1093/annonc/mdp467. Epub 2009 Nov 10.

DOI:10.1093/annonc/mdp467

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?

Ann Oncol. 2010 Jan;21(1):183-4. doi: 10.1093/annonc/mdp467. Epub 2009 Nov 10.

2

Therapy for metastatic RCC--questions remain.转移性肾细胞癌的治疗——问题依然存在。

Nat Rev Urol. 2009 Nov;6(11):580-1. doi: 10.1038/nrurol.2009.210.

3

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.CCR药物更新：索拉非尼和舒尼替尼用于肾细胞癌

Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.

4

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.舒尼替尼和索拉非尼序贯治疗转移性肝细胞癌。

Invest New Drugs. 2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. Epub 2011 Jul 1.

5

About sorafenib in castration-resistant prostate cancer.关于索拉非尼在去势抵抗性前列腺癌中的应用。

Ann Oncol. 2008 Oct;19(10):1812-3; author reply 1813-1814. doi: 10.1093/annonc/mdn546. Epub 2008 Aug 9.

6

Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.摘取低垂的果实：用于治疗晚期髓样甲状腺癌和非髓样甲状腺癌的激酶抑制剂

J Clin Endocrinol Metab. 2010 Jun;95(6):2621-4. doi: 10.1210/jc.2010-0800.

7

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.酪氨酸激酶抑制剂（舒尼替尼、索拉非尼、达沙替尼和伊马替尼）对一般临床实践中糖尿病和非糖尿病患者血糖水平的影响。

J Oncol Pharm Pract. 2011 Sep;17(3):197-202. doi: 10.1177/1078155210378913. Epub 2010 Aug 4.

8

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.舒尼替尼和索拉非尼在转移性肾细胞癌治疗中的作用。

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661.

9

Sorafenib and sunitinib.索拉非尼和舒尼替尼。

Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.

10

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.比较舒尼替尼与索拉非尼在人肝癌异种移植模型中的疗效：机制解释。

Curr Cancer Drug Targets. 2011 Oct;11(8):944-53. doi: 10.2174/156800911797264716.

引用本文的文献

1

Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.调节 Akt/mTOR 信号通路可克服肾和前列腺癌细胞对舒尼替尼的耐药性。

Mol Cancer Ther. 2012 Jul;11(7):1510-7. doi: 10.1158/1535-7163.MCT-11-0907. Epub 2012 Apr 24.

2

Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.白细胞介素-6：雄激素剥夺性前列腺癌对多靶点受体酪氨酸激酶抑制剂耐药的潜在生物标志物。

Urology. 2011 Oct;78(4):968.e7-11. doi: 10.1016/j.urology.2011.07.1384.